Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $12.7 million.

  • Fennec Pharmaceuticals' Operating Expenses rose 390.11% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.5 million, marking a year-over-year decrease of 883.48%. This contributed to the annual value of $45.0 million for FY2024, which is 3217.53% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Operating Expenses stood at $12.7 million, which was up 390.11% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Operating Expenses registered a high of $12.7 million during Q3 2025, and its lowest value of -$5.0 million during Q2 2022.
  • Its 5-year average for Operating Expenses is $7.8 million, with a median of $8.1 million in 2022.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 22778.06% in 2022, then surged by 25953.28% in 2023.
  • Fennec Pharmaceuticals' Operating Expenses (Quarter) stood at $4.2 million in 2021, then skyrocketed by 97.39% to $8.2 million in 2022, then skyrocketed by 40.26% to $11.6 million in 2023, then fell by 23.32% to $8.9 million in 2024, then skyrocketed by 42.8% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $12.4 million for Q2 2025, and $9.6 million during Q1 2025.